UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Beyond the AJR : 99m Tc-MDP Bone Scintigraphy-Has It Met Its Match?

American journal of roentgenology (1976), 2023-08, Vol.221 (2), p.281

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)

Clinical cancer research, 2017-12, Vol.23 (23), p.7199-7208

2017

Link zum Volltext

Verfügbarkeit prüfen

Anaplastic Thyroid Carcinoma, Version 2.2015

Journal of the National Comprehensive Cancer Network, 2015-09, Vol.13 (9), p.1140

2015

Link zum Volltext

Verfügbarkeit prüfen

Thyroid carcinoma

Journal of the National Comprehensive Cancer Network, 2010-11, Vol.8 (11), p.1228

2010

Link zum Volltext

Verfügbarkeit prüfen

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody

The Journal of nuclear medicine (1978), 2002-02, Vol.43 (2), p.267

2002

Link zum Volltext

Verfügbarkeit prüfen

Radioguided Detection of Lymph Node Metastasis in Non-Small Cell Lung Cancer

The Annals of thoracic surgery, 2006-11, Vol.82 (5), p.1815-1820

2006

Link zum Volltext

Verfügbarkeit prüfen

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Critical reviews in oncology/hematology, 2001-07, Vol.39 (1), p.181-194

2001

Link zum Volltext

Verfügbarkeit prüfen

Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters

The oncologist (Dayton, Ohio), 2023-03, Vol.28 (3), p.246-251

2023

Link zum Volltext

Verfügbarkeit prüfen

Thyroid carcinoma, version 2.2014

Journal of the National Comprehensive Cancer Network, 2014-12, Vol.12 (12), p.1671

2014

Link zum Volltext

Verfügbarkeit prüfen

Thyroid carcinoma

Journal of the National Comprehensive Cancer Network, 2007-07, Vol.5 (6), p.568

2007

Link zum Volltext

Verfügbarkeit prüfen

Radiation dosimetry results for zevalin radioimmunotherapy of rituximab‐refractory non‐hodgkin lymphoma

Cancer, 2002-02, Vol.94 (S4), p.1349-1357

2002

Link zum Volltext

Verfügbarkeit prüfen

Sentinel node biopsy in breast cancer

Annals of surgical oncology, 1998-03, Vol.5 (2), p.126-130

1998

Link zum Volltext

Verfügbarkeit prüfen

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma

Journal of clinical oncology, 2014-09, Vol.32 (25), p.2705-2711

2014

Link zum Volltext

Verfügbarkeit prüfen

Preoperative imaging for metastasectomy

Surgical oncology clinics of North America, 2007-07, Vol.16 (3), p.471

2007

Link zum Volltext

Verfügbarkeit prüfen

Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era - tissue remains the issue

Leukemia & lymphoma, 2020-11, Vol.61 (13), p.3226-3233

2020

Link zum Volltext

Verfügbarkeit prüfen

Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules

Journal of hematology and oncology, 2008-09, Vol.1 (1), p.13-13, Article 13

2008

Link zum Volltext

Verfügbarkeit prüfen

Prediction of outcome to 223-Ra treatment of castration-resistant prostate cancer using disease burden on quantitative bone scan

The Journal of nuclear medicine (1978), 2018-05, Vol.59, p.1491

2018

Link zum Volltext

Verfügbarkeit prüfen

Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16513-e16513

2017

Link zum Volltext

Verfügbarkeit prüfen

sup 18^F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab

The Journal of nuclear medicine (1978), 2017-01, Vol.58 (1), p.62

2017

Link zum Volltext

Verfügbarkeit prüfen

18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab

The Journal of nuclear medicine (1978), 2017-01, Vol.58 (1), p.62-68

2017

Link zum Volltext

Verfügbarkeit prüfen

super( 18)F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab

The Journal of nuclear medicine (1978), 2017-01, Vol.58 (1), p.62-62

2017

Link zum Volltext

Verfügbarkeit prüfen

18 F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine–Rituximab

Journal of Nuclear Medicine, 2017-01, Vol.58 (1), p.62-68

2017

Link zum Volltext

Verfügbarkeit prüfen

Medullary carcinoma

Journal of the National Comprehensive Cancer Network, 2010-05, Vol.8 (5), p.512

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(58)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(29)
Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Oncology
(15)
Male
(13)
Aged
(11)
Female
(11)
Middle Aged
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Adult
(9)
Neoplasm Staging
(9)
Fluorodeoxyglucose F18
(8)
Prognosis
(8)
Radiopharmaceuticals
(7)
Lymphatic Metastasis
(6)
Hematology
(5)
Positron-Emission Tomography - Methods
(5)
Predictive Value Of Tests
(5)
Thyroid Neoplasms - Pathology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Beyond the AJR : 99m Tc-MDP Bone Scintigraphy-Has It Met Its Match?

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)

Anaplastic Thyroid Carcinoma, Version 2.2015

Thyroid carcinoma

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody

Radioguided Detection of Lymph Node Metastasis in Non-Small Cell Lung Cancer

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters

Thyroid carcinoma, version 2.2014

Thyroid carcinoma

Radiation dosimetry results for zevalin radioimmunotherapy of rituximab‐refractory non‐hodgkin lymphoma

Sentinel node biopsy in breast cancer

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma

Preoperative imaging for metastasectomy

Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era - tissue remains the issue

Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules

Prediction of outcome to 223-Ra treatment of castration-resistant prostate cancer using disease burden on quantitative bone scan

Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment

sup 18^F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab

18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab

super( 18)F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab

18 F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine–Rituximab

Medullary carcinoma

Optimizing Dosimetry Imaging in High-dose Radioimmunotherapy Using the Novel, Anti-CD45 Re-induction and Targeted Conditioning Agent Iodine (131I) Apamistamab [Iomab-B] in Patients 55 Years or Older with Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA Phase III Trial)

Suchergebnisse filtern